Posttransplant management of recipients undergoing liver transplantation for hepatocellular carcinoma. Working Group Report from the ILTS Transplant Oncology Consensus Conference
Berenguer M (1), Burra P (2), Ghobrial M (3), Hibi T (4), Metselar H (5), Sapisochin G (6), Bhoori S (7), Man NK (8), Mas V (9), Ohira M (10), Sangro B (11), van der Laan LJW (12).
Although liver transplantation (LT) is the best treatment for patients with localized hepatocellular carcinoma (HCC), recurrence occurs in 6%-18% of patients.
Several factors, particularly morphological criteria combined with dynamic parameters, known prior to LT modify this risk and combined in prediction models may be used to stratify patients at need of variable surveillance strategies.
Additional variables though likely explain differences in recurrence rates in patients with the same pre-LT HCC status. One of these variables is possibly immunosuppression (IS). Once recurrence takes place, management is highly heterogenous. Within the ILTS Consensus Conference on Liver Transplant Oncology, working group 4 aim was to analyse the data regarding posttransplant management of recipients undergoing LT for HCC.
Three areas of research were considered: (1) cancer prediction models and surveillance strategies; (2) tailored IS for cancer recipients; and (3) new adjuvant therapies for HCC recurrence.
Following formulation of several questions, a literature search was undertaken with abstract review followed by article retrieval and full-data extraction. The GRADE system was used for evidence rating incorporating strength of recommendation and quality of evidence.
CITA DEL ARTÍCULO Transplantation. 2020 Mar 23. doi: 10.1097/TP.0000000000003196